Double Blind Placebo Controlled Study of Outpatient Intravenous Ketamine for the Treatment of CRPS
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
Complex Regional Pain Syndrome is a debilitating and extremely difficult to treat condition.
There is a large body of evidence demonstrating the therapeutic value of N-methyl-D-aspartate
(NMDA)-receptor antagonists in CRPS. The NMDA antagonist ketamine has been shown to be
effective in the treatment of CRPS, resulting in complete remission of the disease in some
patients. The purpose of this study is to evaluate intravenous outpatient infusion of
sub-anesthetic doses of ketamine for the treatment of CRPS. A thorough evaluation of this
procedure, providing information into the degree of relief and which of the constellation of
RSD symptoms are best alleviated by this procedure would result in the optimization of this
therapy for the treatment of CRPS.